Clett Erridge

Clett Erridge is a Senior Lecturer in Immunology at Anglia Ruskin University within the Faculty of Science and Engineering and School of Life Sciences, based in Cambridge. He is an active member of the Biomedical Research Group whose work bridges innate immunity, lipid metabolism, and chronic disease mechanisms.

His academic foundation includes:

• PhD in Molecular Immunology, University of Edinburgh (2003)
• BSc (Hons) Molecular Biology, University of Edinburgh (1997)

Dr. Erridge's research centers on molecular mechanisms linking inflammation to lipid metabolism in coronary artery disease, with parallel investigation into macrophage-mediated tumor cell phagocytosis for cancer immunotherapy. Key emphases include:

• Pattern-recognition receptor signaling in macrophage lipid metabolism
• Microbiota-derived regulation of innate immunity
• Therapeutic development for atherosclerosis and cancer immunotherapy

His publication trajectory reveals consistent focus on Toll-like receptor pathways across metabolic and inflammatory diseases, evolving from dietary impacts on endotoxemia to novel cancer immunotherapies through macrophage reprogramming.

Professional recognition includes:

• Fellow, Higher Education Academy

Dr. Erridge actively supervises PhD candidates in atherosclerosis and cancer immunotherapy while securing substantial research funding. His grant portfolio demonstrates translational focus:

• Determining the mechanism of action of a therapeutic antibody targeting annexin pathways (Oncobiopharm Ltd, £123,000, 2018-19)
• Diet-dependent regulation of innate immune function in atherosclerosis (Iraq government, £54,000, 2013-16)
• Investigation of dietary TLR-stimulants in murine atherogenesis (Wellcome Trust, £6,000, 2013)

His laboratory within the Biomedical Research Group employs cellular and animal models to dissect molecular pathways connecting innate immunity to metabolic diseases, with growing emphasis on macrophage-based cancer therapeutics.